
Tamsulosin (0.4mg) + Dutasteride (0.5mg)
Active composition
+1 more active ingredient
Tamsulosin selectively antagonizes alpha-1 adrenergic receptors in the prostate and bladder neck, leading to smooth muscle relaxation and improved urine flow.
Dutasteride inhibits both type I and type II 5-alpha reductase enzymes, decreasing DHT levels and prostate growth.
Medical applications
Kypros D Tablet ER is a combination medication containing Tamsulosin 0.4 mg and Dutasteride 0.5 mg, formulated as an extended-release tablet for the management of benign prostatic hyperplasia (BPH). Tamsulosin is an alpha-1 adrenergic receptor antagonist that selectively relaxes smooth muscle in the prostate and bladder neck, improving urinary flow and reducing symptoms associated with BPH. Dutasteride is a 5-alpha-reductase inhibitor that decreases the conversion of testosterone to dihydrotestosterone (DHT), leading to a reduction in prostate volume over time. The combined action of these agents addresses both the dynamic and static components of BPH, providing symptomatic relief and reducing the risk of disease progression. Kypros D Tablet ER is indicated for men with moderate to severe BPH who may benefit from dual therapy to improve urinary symptoms and decrease the need for surgical intervention. The extended-release formulation ensures a steady plasma concentration, enhancing patient compliance by allowing once-daily dosing. Common adverse effects may include dizziness, headache, ejaculation disorders, and potential hypersensitivity reactions. Use of Kypros D should be under medical supervision, with periodic monitoring of prostate-specific antigen (PSA) levels recommended to detect any changes suggestive of prostate malignancy.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Information regarding the use of Kypros D Tablet ER during pregnancy is not available. Please consult your doctor.
High Risk
Information regarding the use of Kypros D Tablet ER during breastfeeding is not available. Please consult your doctor.
Medical Advice
There is limited information available on the use of Kypros D Tablet ER in patients with kidney disease. Please consult your doctor.
Exercise Caution
Kypros D Tablet ER may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.
Consult Doctor
Kypros D Tablet ER should be used with caution in patients with liver disease. Dose adjustment of Kypros D Tablet ER may be needed. Please consult your doctor. Use of Kypros D Tablet ER is not recommended in patients with severe liver disease.
Regular Checkup
0 reviews for Kypros D Tablet ER

Tamsulosin (0.4mg) + Dutasteride (0.5mg)
Cheaper alternative availability
This medicine doesn't have a cheaper alternative with the same composition. Our health advisors can help you find other savings options based on your prescription.
Active composition
+1 more active ingredient
Tamsulosin selectively antagonizes alpha-1 adrenergic receptors in the prostate and bladder neck, leading to smooth muscle relaxation and improved urine flow.
Dutasteride inhibits both type I and type II 5-alpha reductase enzymes, decreasing DHT levels and prostate growth.
Medical applications
Kypros D Tablet ER is a combination medication containing Tamsulosin 0.4 mg and Dutasteride 0.5 mg, formulated as an extended-release tablet for the management of benign prostatic hyperplasia (BPH). Tamsulosin is an alpha-1 adrenergic receptor antagonist that selectively relaxes smooth muscle in the prostate and bladder neck, improving urinary flow and reducing symptoms associated with BPH. Dutasteride is a 5-alpha-reductase inhibitor that decreases the conversion of testosterone to dihydrotestosterone (DHT), leading to a reduction in prostate volume over time. The combined action of these agents addresses both the dynamic and static components of BPH, providing symptomatic relief and reducing the risk of disease progression. Kypros D Tablet ER is indicated for men with moderate to severe BPH who may benefit from dual therapy to improve urinary symptoms and decrease the need for surgical intervention. The extended-release formulation ensures a steady plasma concentration, enhancing patient compliance by allowing once-daily dosing. Common adverse effects may include dizziness, headache, ejaculation disorders, and potential hypersensitivity reactions. Use of Kypros D should be under medical supervision, with periodic monitoring of prostate-specific antigen (PSA) levels recommended to detect any changes suggestive of prostate malignancy.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Information regarding the use of Kypros D Tablet ER during pregnancy is not available. Please consult your doctor.
High Risk
Information regarding the use of Kypros D Tablet ER during breastfeeding is not available. Please consult your doctor.
Medical Advice
There is limited information available on the use of Kypros D Tablet ER in patients with kidney disease. Please consult your doctor.
Exercise Caution
Kypros D Tablet ER may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.
Consult Doctor
Kypros D Tablet ER should be used with caution in patients with liver disease. Dose adjustment of Kypros D Tablet ER may be needed. Please consult your doctor. Use of Kypros D Tablet ER is not recommended in patients with severe liver disease.
Regular Checkup
0 reviews for Kypros D Tablet ER















